Chronic kidney disease in long-term survivors of hematopoietic cell transplant

被引:105
作者
Hingorani, S.
Guthrie, K. A.
Schoch, G.
Weiss, N. S.
McDonald, G. B.
机构
[1] Univ Washington, Dept Med, Seattle, WA 98195 USA
[2] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Pediat, Seattle, WA 98105 USA
[4] Fred Hutchinson Canc Res Ctr, Dept Clin Res & Biostat, Seattle, WA 98104 USA
关键词
chronic kidney disease; risk factors; hematopoietic cell transplant;
D O I
10.1038/sj.bmt.1705573
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We conducted a cohort study to identify risk factors of chronic kidney disease (CKD) among long-term survivors of hematopoietic cell transplant (HCT). We studied 1635 patients transplanted at the Fred Hutchinson Cancer Research Center (FHCRC) between 1991 and 2002, who survived to day +131 after transplant and had serum creatinine measured on at least two occasions after day +131. CKD was defined as a glomerular filtration rate < 60 ml/min/m(2) on two occasions separated by at least 30 days between days 100 and 540 post transplant. Cox regression models estimated hazard ratios (HRs) describing associations between demographic data, clinical variables and the risk of developing CKD. A total of 376 patients (23%) developed CKD at a median of 191 days post transplant (range 131-516 days). An increased risk of CKD was associated with acute renal failure (ARF) (HR = 1.7, 95% confidence interval (CI) 1.3-2.1), acute graft-vs-host disease (aGVHD) grade II (HR = 2.0, 95% CI 1.4-2.9) and grades III/IV (HR = 3.1, 95% CI 2.1-4.6) and chronic GVHD (HR = 1.8, 95% CI 1.4-2.2). Total body irradiation (TBI) (HR = 1.0, 95% CI 0.8-1.3) was not associated with an increased risk of CKD. CKD is relatively common among survivors of HCT. The presence of ARF and GVHD, but not receipt of TBI, appears to be associated with the occurrence of CKD.
引用
收藏
页码:223 / 229
页数:7
相关论文
共 44 条
[1]   DELAYED RENAL-FAILURE WITH EXTENSIVE MESANGIOLYSIS FOLLOWING BONE-MARROW TRANSPLANTATION [J].
ANTIGNAC, C ;
GUBLER, MC ;
LEVERGER, G ;
BROYER, M ;
HABIB, R ;
LACOSTE, M ;
BEZIAU, A ;
NAIZOT, C .
KIDNEY INTERNATIONAL, 1989, 35 (06) :1336-1344
[2]  
BROWN JM, 2004, HEMATOPOIETIC CELL T, P683
[3]  
BUCKNER DC, 1999, HEMATOPOIETIC CELL T, P123
[4]   Mini-allografts: ongoing trials in humans [J].
Carella, AM ;
Champlin, R ;
Slavin, S ;
McSweeney, P ;
Storb, R .
BONE MARROW TRANSPLANTATION, 2000, 25 (04) :345-350
[5]  
Chao N. J., 2005, GRAFT VS HOST DIS, P459
[6]   End-stage renal disease (ESRD) after bone marrow transplantation: Poor survival compared to other causes of ESRD [J].
Cohen, EP ;
Piering, WF ;
Kabler-Babbitt, C ;
Moulder, JE .
NEPHRON, 1998, 79 (04) :408-412
[7]   BONE-MARROW TRANSPLANT NEPHROPATHY - RADIATION NEPHRITIS REVISITED [J].
COHEN, EP ;
LAWTON, CA ;
MOULDER, JE .
NEPHRON, 1995, 70 (02) :217-222
[8]   Acute graft-versus-host disease: Pathophysiology, clinical manifestations, and management [J].
Couriel, D ;
Caldera, H ;
Champlin, R ;
Komanduri, K .
CANCER, 2004, 101 (09) :1936-1946
[9]   Effect of colchicine on cyclosporine nephrotoxicity, reduction of TGF-beta overexpression, apoptosis, and oxidative damage: An experimental animal study [J].
Disel, U ;
Paydas, S ;
Dogan, A ;
Gulfiliz, G ;
Yavuz, S .
TRANSPLANTATION PROCEEDINGS, 2004, 36 (05) :1372-1376
[10]   Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation [J].
El Seisi, S ;
Gupta, R ;
Clase, CM ;
Forrest, DL ;
Milandinovic, M ;
Couban, S .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (11) :683-688